Alkermes plc (ALKS) vs GH Research PLC (GHRS)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ALKS | GHRS | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Size band | MID | SMALL |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | Ireland | Ireland |
| Theme | neuroscience | psychedelic-therapeutics |
| Price and returns | ||
| Last close | $44.44 | $19.18 |
| Return · 1 week | +3.42% | +4.92% |
| Return · 1 month | +10.68% | −18.10% |
| Return · 3 months | −12.00% | −31.40% |
| Return · year to date | +57.25% | +44.86% |
| Return · 1 year | +49.53% | +33.99% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −20.17% | −38.99% |
| 52-week high | $55.67 | $31.44 |
| 52-week low | $27.00 | $12.04 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $7.46B | $1.32B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $69.27M | $4.03M |
| Employees | 2,050 | 73 |
| Valuation | ||
| Price to earnings · trailing | 108.47× | n/a (negative earnings) |
| Price to earnings · forward | 22.80× | n/a (negative forward earnings) |
| Price to sales | 4.15× | — |
| Price to book | 3.82× | 3.45× |
| Enterprise value to EBITDA | 27.48× | n/a (negative value) |
| Enterprise value to revenue | 4.70× | — |
| PEG ratio | 1.96 | — |
| Earnings per share · trailing | 0.38 | -0.99 |
| Profitability | ||
| Gross margin | 84.56% | — |
| Operating margin | 15.50% | 0.00% |
| Profit margin | 3.97% | — |
| Return on equity | 3.85% | −18.79% |
| Return on assets | 4.20% | −13.02% |
| Growth | ||
| Revenue growth | +27.00% | — |
| Earnings growth | −99.40% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 86.95 | 0.10 |
| Current ratio | 2.30 | 28.70 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | — |
| Trend and volatility | ||
| RSI · 14 | 57.78 | 36.54 |
| ADX · 14 | 25.58 | 42.64 |
| 50-day average | $44.40 | $24.76 |
| 200-day average | $40.17 | $21.45 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.31% | 5.61% |
The full ALKS analysis
Everything this table leaves out for Alkermes plc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ALKS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ALKS analysisThe full GHRS analysis
Everything this table leaves out for GH Research PLC: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the GHRS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full GHRS analysis